Multiple Sclerosis is the most common immune-mediated inflammatory demyelinating disease of the central nervous system. Educational gaps involving early symptom identification and diagnosis, misdiagnosis, current concepts of neurologic reserve and benefits of early treatment, a rapidly evolving treatment landscape, and increasing goals of therapy create real-world challenges for HCPs that threaten the long-term prognosis of individuals living with MS.
- Podcast Episodes
- Explainer Video
- Interactive e-Learning Module
Brought to you by Stanford CME & Dr. Lucas Kipp
Dr. Kipp specializes in the diagnosis and treatment of neuroimmunological disorders, particularly demyelinating conditions such as multiple sclerosis and neuromyelitis optica. He is interested in translational research connecting expert MS clinicians, world-renown immunology laboratories, and advanced neuroimaging techniques to identify biomarkers of disease and treatment response.